Endothelial dysfunction is a central mechanism driving vascular complications in diabetes and hypertension, highlighting it as a potential therapeutic target.
Answers are grounded in this paper and cite their sources.
Caution against premature clinical adoption; leaves open validation of endothelial-targeted therapies in prospective trials.
Endothelial dysfunction plays a key role in the initiation of cellular events evolving into the development of vascular complications in diabetes and hypertension. Diminished production and function of endothelium-derived nitric oxide and other vasoprotective factors and/or the exaggerated production of proinflammatory and vasoconstrictors such as angiotensin II, endothelin-1, reactive oxygen species, and cyclooxygenase-derived metabolites of arachidonic acid eventually lead to endothelial dysfunction, resulting in elevated vascular tone which contributes to hypertension, vascular, and cardiac remodeling, culminating in microvascular, macrovascular, and renal damages. Specific therapies targeting reactive oxygen species using antioxidants and inhibitors of the rennin-angiotensin system or increasing endothelial nitric oxide synthase activity might assist to reverse endothelial dysfunction and thus reduce the related cardiovascular morbidity and mortality in diabetes and hypertension.
No takes yet. Share an insight, caveat, or question.
Wong et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: